Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancer

BACKGROUND: The investigational oral DNA vaccine VXM01 targets the vascular endothelial growth factor receptor 2 (VEGFR-2) and uses Salmonella typhi Ty21a as a vector. The immune reaction elicited by VXM01 is expected to disrupt the tumor neovasculature and, consequently, inhibit tumor growth. VXM01...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Niethammer, Andreas G, Lubenau, Heinz, Mikus, Gerd, Knebel, Philipp, Hohmann, Nicolas, Leowardi, Christine, Beckhove, Philipp, Akhisaroglu, Mustafa, Ge, Yingzi, Springer, Marco, Grenacher, Lars, Buchler, Markus W, Koch, Moritz, Weitz, Jürgen, Haefeli, Walter E, Schmitz-Winnenthal, Friedrich H
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2012
Teme:
Study Protocol
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3493262/
https://ncbi.nlm.nih.gov/pubmed/22906006
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-12-361
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki